Related Experiment Video
Updated: Jan 18, 2026
08:07
Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
Published on: September 6, 2017
10.6K
The Hunt for HLA-DQ Allogeneic Eplets Is Not Over: Four New Ones, Including a Cross-Chain Eplet
Magali Devriese1,2, Diego Amaya-Ramirez3, Tina Meng4
1Laboratoire D'immunologie et Histocompatibilité, Hôpital Saint Louis, Paris, France.
HLA
|September 12, 2025
Summary
Researchers identified and validated four new human leukocyte antigen (HLA) eplets, which are key targets for anti-HLA antibodies. This discovery enhances understanding of antibody binding in transplantation by confirming eplet realness through advanced methods.
Area of Science:
- Immunology
- Genetics
- Biochemistry
Background:
- Anti-HLA antibodies target specific epitopes, particularly polymorphic eplets on HLA molecules.
- The HLA Eplet Registry contains over 550 deduced HLA eplets, but verification is ongoing.
- Identifying novel, validated eplets is crucial for understanding HLA antibody responses.
Purpose of the Study:
- To systematically analyze DQ antigens for novel polymorphic amino acids as candidate eplets.
- To validate newly identified DQB1 and DQA1/DQB1 overlapping eplets using patient sera.
- To explore the role of molecular accessibility and flexibility in antibody binding to HLA eplets.
Main Methods:
- Systematic sequence alignment analysis of DQ antigens.
- Luminex single antigen bead assays (LABScreen, Lifecodes) for serum antibody profiling.
- Antibody adsorption and elution using human cells and HLA-DQ transfected murine cell clones.
- 3D modeling for eplet localization and accessibility assessment.
Main Results:
- Three novel DQB1 eplets and one DQA1/DQB1 overlapping eplet were identified and validated.
- Serum antibody profiles consistently implicated these residues.
- Adsorption-elution experiments confirmed antibody binding to the validated eplets.
- 3D modeling indicated variable accessibility and potential influence of molecular flexibility on antibody binding.
Conclusions:
- A combined strategy of Luminex assays, cell-based validation, and in silico modeling effectively confirms novel HLA eplets.
- Four new HLA eplets have been validated, contributing to a more comprehensive understanding of HLA antibody targets.
- Molecular accessibility alone may not fully predict antibody binding due to dynamic flexibility.
